For example, DLL3 has emerged as a critical therapeutic target for SCLC, with related antibody‐drug conjugates and bispecific T‐cell engagers demonstrating promising anti‐tumour activity in clinical trials.198. This evidence concerns the gene DLL3 and neoplasm.